|
06 Jan 2022 |
POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies
|
|
06 Jan 2022 |
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
|
|
06 Jan 2022 |
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
|
|
05 Jan 2022 |
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
|
|
05 Jan 2022 |
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
|
|
03 Jan 2022 |
Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics
|
|
29 Dec 2021 |
AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
|
|
28 Dec 2021 |
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
|
|
22 Dec 2021 |
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
|
|
22 Dec 2021 |
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
|
|
22 Dec 2021 |
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
|
|
21 Dec 2021 |
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
|
|
21 Dec 2021 |
Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
|
|
17 Dec 2021 |
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
|
|
17 Dec 2021 |
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
|
|
16 Dec 2021 |
Rakuten Medical Announces FDA Acceptance of an Investigational New Drug (IND) Application for RM-1995, a Conjugate of IR700 and anti-CD25 Antibody
|
|
16 Dec 2021 |
Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy
|
|
14 Dec 2021 |
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
|
|
14 Dec 2021 |
Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
|
|
14 Dec 2021 |
CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd
|
|
14 Dec 2021 |
Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
|
|
13 Dec 2021 |
Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products
|
|
13 Dec 2021 |
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
|
|
13 Dec 2021 |
Pfizer to Acquire Arena Pharmaceuticals
|
|
10 Dec 2021 |
Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
|
